Trials / Conditions / MPN (Myeloproliferative Neoplasms)

MPN (Myeloproliferative Neoplasms)

11 registered clinical trials studyying MPN (Myeloproliferative Neoplasms) — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225	MPN Research Foundation	—
Recruiting	Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation NCT06892223	Istituto Clinico Humanitas	Phase 2
Completed	A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Pa NCT03144687	Incyte Corporation	Phase 2
Terminated	Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to NCT03123588	Incyte Corporation	Phase 2
Completed	A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neop NCT03011372	Incyte Corporation	Phase 2
Terminated	A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis NCT02718300	Incyte Corporation	Phase 2
Completed	Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) NCT02953704	Incyte Corporation	—
Completed	Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) NCT02252159	Incyte Corporation	—
Completed	An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis NCT01633372	Incyte Corporation	Phase 2
Completed	Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myel NCT01348490	Incyte Corporation	Phase 2
Completed	COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial NCT00952289	Incyte Corporation	Phase 3